Huntington’s Disease Treatment Market

Huntington’s disease Treatment Market Outlook (2022 to 2032)

The global Huntington’s disease treatment market was estimated to have a market size worth US$ 360 Million in 2021 and is expected to grow at a CAGR of 20% from 2022 to 2032.

The market is estimated to reach US$ 2.7 Billion by the end of 2032.

The Huntington’s disease (HD) Treatment Market is expected to grow during the forecast period, reaching a global market size of US$ 432 Mn by the end of 2022.

Huntington’s disease affects approximately 31,000 people in North America, with a prevalence of 5.8 per 100,000 people. Ingrezza's expected label expansion to include chorea associated with Huntington's disease, together with the high incidence of Huntington’s disease in western countries, is anticipated to be major market drivers.

The prevalence of Huntington’s disease in children is much lower, with around 5.1% to 10% of all cases. The prevalence of HD in Europe is ten in 100,000

Report Attributes	Details
Market Size in 2021	US$ 360 Million
Market Size in 2022	US$ 432 Million
Forecasted Market Value in 2032	US$ 2.7 Billion
CAGR during the forecast period, 2022 to 2032	20%
Market Share North America Expected During 2022	77%
Key Players Offering Treatment for Huntington’s Disease	H. Lundbeck A/S; Bausch Health Companies Inc.; Hetero Drugs; Lupin Limited; Hikma Pharmaceuticals Plc.; Dr. Roddy’s Laboratories Ltd.; Sun Pharmaceutical Industries Ltd.

Demand Analysis of Huntington’s Disease Treatment, 2015 to 2021 vs. Market Outlook 2022 to 2032

The global market for Huntington’s disease treatment expanded at a compound annual growth rate of 15.6% between 2015 and 2021, according to market research and competitive intelligence provider Fact.MR.

North-America was the dominant regional market during this time and held a significant share of global demand.

The market witnessed a slow growth rate of 7% from 2019 to the middle of 2020 due to the global COVID-19 pandemic. During the COVID-19 pandemic, online pharmacies were selling off-label drugs to manage symptoms associated with HD, such as antipsychotics, antidepressants, and anticonvulsants. Clinical trials were delayed during the COVID-19 pandemic due to the government-imposed blackout.

From 2022 and 2023, the market is forecast to grow at a y-o-y rate of 6.5%. According to most hospitals and clinics worldwide, the frequency of clinical visits for the diagnosis and treatment of HD has increased post the second quarter of 2021.

Because of this, the market will continue to grow with the expected growth rate beyond COVID-19. In the aftermath of the pandemic, clinical trials to develop a treatment for Huntington's disease have increased.

What are the specific drivers of the Huntington’s disease Treatment Market?

Growing Adoption of Improved Medical Treatments and Therapies to Drive Demand for Effective Treatments

Market growth is expected to be driven by the involvement of major market players in research for a cure for Huntington's disease (HD). There is a growing patient population and prevalence of diseases worldwide, mainly in North America and Europe. There will be further positive contribution to the market growth from the lack of disease-modifying drugs and other treatment methods available to HD patients.

As a potentially effective treatment for HD, stem cell therapy is generating interest. The ADORE-DH phase 2/ 3 trial uses CELLAVITA-HD, stem cell therapy being developed by Cellavita in collaboration with AzidusPharma. Additionally, alternative therapy options, such as speech therapy, psychological treatment, and physiotherapy, had a positive impact on the market growth for Huntington's disease treatment market.

Growing R&D Activities to accelerate the Market Growth

Research and development of Huntington's disease treatment methods continues to be made easier by the lack of a proper treatment or medication for the disease. This is expected to boost market growth significantly over the forecast period. Furthermore, government initiatives that encourage the development of new drugs are an important driver of the market's growth.

Global Huntington's disease treatment market is expected to grow due to increasing prevalence of disease and increased R&D activities by institutes and universities during the forecast period. The Huntington's disease Society of America estimates that there are approximately 30,000 symptomatic Americans and more than 200,000 people at risk for inheriting the disease.

Annexon Inc., for example, is developing ANX005-an experimental monoclonal antibody that addresses abnormal C1q activity in certain complement-mediated neurodegenerative diseases, such as Huntington's disease. In this innovative medication, C1q is suppressed along with the classical complement system, and it is administered intravenously (IV). The company started a phase 2 clinical trial of ANX005 in November 2020 to treat HD patients.

Failed therapies can be a significant threat to this market

The development of HD-specific therapies has been plagued by significant obstacles as several therapies have either failed to demonstrate efficacy or caused dangerous side effects. The Phase III trial GENERATION HD1 showed tominersen did not improve the symptoms of manifest HD, as F Hoffmann-La Roche Ltd discontinued the study in March 2021.

Data from phase III research has been analyzed by an unblinded Independent Data Monitoring Committee (iDMC) based on preliminary findings from that research. Upon analyzing these data, there was no indication of new or evolving safety signals for Tominersen.

The COVID-19 pandemic has had a slight negative impact on the market for Huntington's disease treatments. Clinical trials may be delayed due to the pandemic, which can delay the entry of pipeline candidates into the market.

Country-wise-Analysis

How will the growth emerge in the North American region during the forecast period?

Various measures towards preventing HD will drive this growth

In 2022, the North American market is expected to account for 77% of global revenue for Huntington's disease treatments. The increase in awareness and sales of Huntington's disease treatment products are a result of the high prevalence of Huntington's disease, the increased healthcare expenditure, technological advances, and proactive government initiatives.

Some of the major players in the market, including H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., have introduced symptom management products to support market growth.

What will be the market outlook in the APAC region?

Increasing product penetration will account for steady growth

Due to increasing product penetration, potential for growth, and growth in the prevalence of Huntington's disease in developing countries, the Asia Pacific market for Huntington's disease treatment is expected to grow rapidly over the forecast period with a projected 45% of the total revenue in this market.

As governments take more initiatives to improve the health status of the population, the market in the region is expected to grow.

Category-wise Insights

What can be expected from the Symptomatic Treatment Segment during the forecast period?

Huntington's disease treatment is expected to dominate the market during the forecast period, with symptomatic treatment to account for 98% of market revenue in 2022.

The growth of this market is attributable to several symptom management products and their patent protection. First-line therapy for Huntington's chorea consists of xenazine and austedo. R&D of potential Huntington's disease product candidates may contribute to the growth of this segment.

In October 2021, SOM BIOTECH's drug SOM3355 was designated an orphan drug by the US Food and Drug Administration for the treatment of chorea associated with Huntington's disease.This is for use in the treatment of chorea associated with Huntington's disease. As a result, the product will be exclusively available in the U.S. after approval by the FDA.

Why is the disease-modifying therapies segment gaining preference?

Advanced therapies will drive this market

The disease-modifying therapies segment is expected to grow at the fastest rate over the forecast period. An increasing demand for advanced products, such as gene therapy and stem cell therapy, along with an increase in research and development for disease-modifying therapy are responsible for this growth.

The government's Fast Track Designation program by the US FDA could lead to accelerated registration processes, fueling the market in the years to come.

As an example, the US Food and Drug Administration granted fast track designation in September 2021 to Sage Therapeutics's candidate drug, SAGE-718, as a potential treatment for Huntington's disease. IQVIA predicts significant growth in US sales of tetrabenazine tablets 12.5 mg and 25 mg in the forecast period of 2022 to 2032.

The disease-modifying therapies segment was valued at US$ 4.2 Bn in 2021 and is projected to reach US$ 9.83 Bn by 2032, growing at a CAGR of 9.1%.

Competitive Landscape

Several key players are adopting various strategies to gain a larger share of the market, including new product development and partnerships.

• Spark Therapeutics, Inc. (a subsidiary of F. Hoffmann La Roche Ltd.) formed a partnership with NeuExcell Therapeutics Inc for the development of gene therapy for treating HD patients in September 2021. NeuExcell Therapeutics will receive upfront license fees, R&D milestone payments, and product royalties up to approximately USD 190 million as part of the agreement.
• Austedo, a drug intended to treat chorea associated with HD by Teva Pharmaceutical Industries Ltd, has been approved by the National Medical Products Association (NMPA) in China in May 2020. After the United States, China has approved AUSTEDO. The company expects to expand its patient base and revenue through this geographical expansion.
• As part of its participation in September 2021, Prilenia Therapeutics B.V. announced its participation in the H.C. Walkewright 23rd Annual Global Investment Conference, Cantor Virtual Global Healthcare Conference, and European Huntington Disease Network to present phase 3 results for candidate pridopidine. Healthcare conferences offer a great opportunity to increase the customer base.

Key Segments Covered in the Industry Survey

• By Treatment

  • Symptomatic Treatment of Huntington’s disease
  • Disease-Modifying Therapies for Huntington’s disease

• By Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA